Scripps research team develops new technique to tap full potential of antibody libraries

In hopes of more fully tapping the libraries' potential, a group of Scripps Research Institute scientists, led by Scripps Research President Richard A. Lerner, M.D., has for the first time developed a new screening technique that enables antibody screening against equally massive libraries of targets. This technique makes it possible to accelerate searches for new treatments against cancer and other diseases.

The work is being reported in this week's Early Edition of the journal Proceedings of the National Academies of Science (PNAS).

The immune system produces antibodies to immobilize invaders, such as bacteria and viruses, by attaching to proteins referred to as antigens on those invaders. For many years, researchers have been producing huge collections of synthetic antibodies that collectively dwarf the number of antibodies humans produce naturally. These resources are a synthetic immune system with almost limitless potential, but existing techniques have only enabled screening the millions upon millions of available antibodies against handfuls of antigens.

"Many scientists have long recognized that efficient and sufficient access to the libraries demands an effective technique for also screening target antigens by the millions," said Lerner. "This work now makes that possible."

Traditional antibody research has involved developing systems in which the antibodies to be tested are incorporated into yeast cells, bacterial viruses known as phages, or some other form of "display" for testing against a target antigen protein. Past attempts to instead screen antibody libraries against antigen libraries have been stymied by a variety of technical challenges.

A key aspect to the success of the Lerner group's technique is using yeast cells to display the antibodies for screening, while using phages for the antigens, with each display labeled by a different colored fluorescent protein.

Screen results are determined using flow cytometry, a technique that allows the researchers to examine images of the yeast cells and phage particles and manipulate them. Using the differing displays means that antibody-antigen pairs that bind can be easily identified, because they show both fluorescent dye tag colors. Bound pairs are then filtered out of the mix for identification of the antibody and antigen involved, which requires genetic sequencing.

"It took us a while to get to the right conditions," says Diana Bowley, Ph.D., a Scripps Research staff scientist and the paper's first author with Teresa Jones, a Scripps Research scientific associate, "but now that we have, it's quite easy to visualize and isolate the antibody-antigen pairs."

To prove the concept, the group focused its initial experiments on a known interaction between a specific antibody and a fragment of a protein found on the outside of HIV particles. The group worked with some 10 million antibodies, but the library was weighted to include a known antibody. The antigen library was of similar size and comparably weighted to include the known HIV antigen. The weighting guaranteed the existence of an antibody-antigen pair, which in turn allowed the group to tweak its initial concept until it could identify pairings at the expected rate.

The group was able to successfully identify the expected pairings, proving the new technique's potential to enable screening of large antibody and antigen libraries. "We're still deciding where to take it next," says Bowley. One likely direction would be to work with a broad group of cancer proteins, which should identify antibodies with potential as new cancer treatments.

###

In addition to Bowley, Jones, and Lerner, Scripps Research Professor Dennis Burton was an author of the paper, titled "Libraries against libraries for combinatorial selection of replicating antigen-antibody pairs."

This research was supported by The Scripps Research Institute, the Skaggs Institute for Chemical Biology, and Pfizer Inc.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California. It also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is currently in the process of moving from temporary facilities to its permanent campus in Jupiter, Florida. Dedication ceremonies for the new campus will be held in February 2009.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.